Key Differences Between PSURs and DSURs in Pharmacovigilance

Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs) are both crucial tools in pharmacovigilance. Although they serve a similar purpose—ongoing evaluation of drug safety—they apply to different stages of a medicinal product’s lifecycle and are governed by distinct guidelines. Understanding the differences between PSURs and DSURs is essential for professionals involved in regulatory affairs, clinical development, and drug safety monitoring.

What is a PSUR?

A PSUR is a report that provides a comprehensive evaluation of the benefit-risk profile of a medicinal product during the post-marketing phase. Governed by ICH E2C(R2), it includes cumulative safety data and is submitted periodically to health authorities such as the EMA and CDSCO (India).

• Purpose: Monitor the ongoing safety of marketed products
• Audience: Regulatory authorities, risk management teams, medical reviewers
• Key output: Benefit-risk assessment, safety signals, and labeling recommendations

What is a DSUR?

A DSUR, on the other hand, is submitted during the clinical development phase and focuses on investigational drugs. It follows ICH E2F guidelines and emphasizes the safety of trial participants.

• Purpose: Monitor safety of investigational drugs during clinical trials
• Audience: Clinical trial sponsors, investigators, regulatory agencies
• Key output: Assessment of safety data from ongoing trials

Side-by-Side Comparison Table

Use Cases: When Do You Submit a PSUR vs DSUR?

PSURs are submitted for authorized, marketed drugs. For example, a company marketing an antihypertensive in the EU must submit a PSUR according to the EURD list schedule.

DSURs are required for drugs in clinical trials. If a new oncology product is undergoing Phase 2 trials across multiple regions, a harmonized DSUR submission is mandatory to regulators including USFDA.

Overlap Between PSUR and DSUR

In some situations—such as ongoing expanded access programs or simultaneous development and marketing—both PSUR and DSUR may be required. Sponsors must:

• Ensure consistent safety messages across both reports
• Coordinate data lock points (DLPs) and submission dates
• Cross-reference overlapping safety signals and risk management actions

Content Differences in Detail

PSUR Content Highlights:

• Cumulative AE data from spontaneous reports
• Post-marketing studies and literature surveillance
• Benefit-risk reevaluation and safety signals
• Labeling changes and market withdrawals

DSUR Content Highlights:

• Investigator Brochure (IB) updates
• Protocol amendments and changes in study design
• Unblinded data summaries (if needed)
• Clinical trial subject disposition and safety outcomes

To maintain SOP compliance, organizations often refer to structured formats from Pharma SOP templates for DSUR and PSUR content standardization.

Global Regulatory Submissions and Harmonization

Some regulatory authorities allow the use of harmonized formats:

• EMA allows PBRER format to replace PSUR
• Japan accepts ICH DSUR format with minor modifications
• CDSCO India and TGA Australia align with ICH guidelines
• FDA permits submission of PSUR content within the Annual Report or PADER

Role of Automation in Managing Both Reports

Modern pharmacovigilance platforms now allow:

• Shared signal detection modules for PSUR and DSUR
• Automated data extraction and tabulation
• Workflow tracking and compliance dashboards
• Combined template-driven authoring environments

For example, tools featured at Pharma Validation support validated report generation processes to meet multiple regional requirements efficiently.

Conclusion

While PSURs and DSURs both serve the common goal of ensuring drug safety, their application, structure, and regulatory expectations differ significantly. PSURs provide a post-marketing perspective, while DSURs focus on clinical development safety. It’s essential for pharma professionals to understand these differences to ensure timely, compliant, and high-quality submissions that meet both regulatory and ethical standards.

Using a combination of internal SOPs, validated templates, and automated tools, organizations can manage PSUR and DSUR requirements more efficiently—supporting both ongoing patient safety and product lifecycle management.

Understanding the Purpose and Structure of a PSUR in Clinical Trials

In clinical trials and post-authorization safety monitoring, a Periodic Safety Update Report (PSUR) is a critical regulatory document that compiles cumulative safety data to evaluate the benefit-risk profile of a medicinal product. Globally harmonized under ICH E2C (R2), the PSUR helps sponsors maintain ongoing pharmacovigilance compliance, detect emerging signals, and communicate risk trends to regulatory authorities like the EMA or USFDA. This tutorial explores the core components, format, and strategic role of PSURs in clinical development and beyond.

What Is a PSUR and Why Is It Important?

The Periodic Safety Update Report is a structured document that summarizes all relevant safety data of an investigational or marketed drug at defined intervals, often every six months or annually. The PSUR aims to:

• Provide a cumulative assessment of the drug’s safety profile
• Identify new safety signals or trends over time
• Evaluate risk minimization measure effectiveness
• Support regulatory decisions for continued development or label changes
• Ensure synchronization between global regulatory expectations

While initially more common in the post-marketing phase, PSURs are increasingly integrated into advanced-stage clinical trial pharmacovigilance planning.

Regulatory Foundation and PSUR Periodicity

As per ICH E2C(R2) and EMA’s Module VII-GVP, PSURs must be submitted periodically for authorized medicinal products. Clinical trial sponsors may be required to submit similar cumulative safety summaries during investigational phases.

Typical PSUR Timelines:

• Initial Post-Authorization: Every 6 months for first 2 years
• Thereafter: Annually for 3 more years
• After Year 5: Every 3 years unless otherwise specified

The frequency can vary depending on country-specific regulations and risk classification of the product.

PSUR vs. PBRER

The term PSUR is often used interchangeably with PBRER (Periodic Benefit-Risk Evaluation Report). While both documents share similar objectives, the PBRER format emphasizes a more comprehensive benefit-risk evaluation aligned with ICH E2C(R2). In the EU, the PBRER is the required format for all PSUR submissions.

In practice, most companies use the PBRER format to fulfill PSUR requirements globally.

Core Structure of a PSUR (PBRER Format)

The PSUR is organized into clearly defined sections. Below is a breakdown of the standard structure:

1. Introduction

Defines the scope, time interval (Data Lock Point), and product summary, including formulation and indications.

2. Worldwide Marketing Authorization Status

Lists all countries where the product is authorized, suspended, or withdrawn, and reasons for any changes.

3. Actions Taken for Safety Reasons

Summarizes regulatory actions based on safety signals, including labeling updates or risk mitigation changes.

4. Changes to Reference Safety Information (RSI)

Describes changes made to the Investigator’s Brochure or Company Core Safety Information (CCSI).

5. Estimated Exposure and Usage Patterns

• Clinical trial exposure by indication and population
• Post-marketing exposure (patient-year estimates)

6. Data in Summary Tabulations

Aggregate safety data across spontaneous reports, literature, and clinical trials, stratified by seriousness and outcome.

7. Summaries of Significant Individual Case Histories

Detailed narratives of key adverse events (AEs), especially fatal or unexpected cases.

8. Signal and Risk Evaluation

Assessment of new, ongoing, or closed signals, with impact on benefit-risk balance.

9. Benefit-Risk Evaluation

Integrated discussion on the evolving benefit-risk profile with scientific justification.

10. Conclusions and Actions

Final assessment and proposed regulatory actions (if any).

Supporting appendices include line listings, literature references, and exposure data.

Data Sources Used in PSURs

PSURs gather safety information from multiple data streams:

• Spontaneous adverse event reporting systems
• Clinical trial databases (CDMS)
• Medical literature (e.g., PubMed, Embase)
• Regulatory databases (e.g., EudraVigilance)
• Stability studies impacting product safety profile
• Ongoing PASS and registries

The comprehensiveness of data significantly influences the accuracy of benefit-risk evaluations.

Common Challenges and Best Practices

Generating a robust PSUR requires cross-functional collaboration between pharmacovigilance, regulatory, clinical, and biostatistics teams. Challenges include:

• Inconsistent data capture across regions or systems
• Late signal detection due to inadequate AE coding
• Version control issues in RSI and labeling history
• Insufficient narrative detail in individual case reports

Best practices to improve PSUR quality include:

1. Automating data aggregation from safety databases
2. Standardizing template and writing SOPs from Pharma SOP templates
3. Conducting regular quality reviews and mock audits
4. Integrating statistical analysis for trend evaluation
5. Including KPIs to assess PSUR impact over time

Submission and Review Timelines

PSURs are submitted electronically through platforms such as the EMA’s EVMPD or FDA’s ESG. Deadlines are defined by the EU Reference Date (EURD) list or by national regulators.

Upon submission, authorities may:

• Accept the report without action
• Request clarifications or additional data
• Mandate changes to SmPC, labeling, or RMP

Maintaining a clear audit trail of submission dates, changes, and follow-up ensures smooth compliance.

Conclusion

The PSUR serves as a cornerstone of pharmacovigilance documentation, enabling a dynamic understanding of product safety in clinical and real-world contexts. By following ICH E2C(R2) standards and leveraging best practices in data collection and narrative analysis, pharmaceutical companies can ensure their PSURs are not only regulatory compliant but also meaningful tools for proactive safety monitoring. Whether in clinical trials or post-marketing phases, a well-structured PSUR aligns all stakeholders in the collective mission of protecting patient health.